Read more at MarketWatch.
Novo Nordisk CEO set to defend Ozempic, Wegovy prices on Capitol Hill
Date: |
Topics
-
CNBC - Business
'Stop ripping us off': Novo Nordisk CEO faces Senate grilling over weight loss drug prices
Sen. Bernie Sanders argues that Novo Nordisk charges Americans substantially higher prices for its drugs than it does for patients in other countries.26 minutes ago -
Financial Times - World
Novo Nordisk faces US Senate grilling over price of weight loss drugs
Senator Bernie Sanders accuses Ozempic and Wegovy maker of ‘ripping off’ AmericansYesterday -
The Hill - Politics
Watch live: Senate HELP committee grills Novo Nordisk on weight loss drug pricing
Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, is set to grill Novo Nordisk CEO Lars Jorgenson Tuesday morning over prices on the ...1 hour ago -
The Hill - Politics
Novo CEO to blame drug middlemen
Presented by Prevent Cancer Foundation — The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss drugs Ozempic and Wegovy. ...17 hours ago -
CNBC - Business
Trump's promise to repeal SALT caps revives the fight on Capitol Hill
House lawmakers from mostly coastal states are preparing for a battle over the SALT deduction. The fight will start to take shape next year.3 days ago - Donald Trump -
NBC News - Top stories
Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs
Is Ozempic and Wegovy maker Novo Nordisk helping Americans save taxpayer money or ripping them off? The company's CEO is scheduled to testify on Capitol Hill Tuesday.6 hours ago
More from MarketWatch
-
MarketWatch - Business
This 34-year-old supersized her salary with her third career
Megan Lewis-Taylor served in the military and law enforcement before going back to college to pursue engineering.14 minutes ago -
MarketWatch - Business
Levi’s CEO says goal of $9 billion to $10 billion in annual revenue by 2027 will be pushed back
Levi Strauss & Co.’s goal of generating $9 billion to $10 billion in annual revenue by 2027 will be pushed back as the denim-clothing company is still seeing pressure on its customer after a long ...22 minutes ago -
MarketWatch - Business
Eli Lilly’s Alzheimer’s treatment Kisunla wins approval in Japan
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s is the most common form of dementia, accounting for more than 67% of ...25 minutes ago - Japan -
MarketWatch - Business
Oil gains after back-to-back losses as China announces stimulus measures
Oil futures rose on Tuesday, looking to post their first gain after back-to-back losses after China announced a range of stimulus measures aimed at boosting the economy of the world’s largest crude ...25 minutes ago - China -
MarketWatch - Business
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
Biogen Inc.’s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial27 minutes ago